Protalix BioTherapeutics, Inc. Research and Development Expense
Protalix BioTherapeutics, Inc. (PLX) reported Research and Development Expense of $4.35 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-12
- Protalix BioTherapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $4.35M, a 27.39% decline year-over-year.
- Protalix BioTherapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $5.43M, a 56.14% increase year-over-year.
- Protalix BioTherapeutics, Inc. research and development expense for the quarter ending 2025-12-31 was $5.63M, a 36.64% increase year-over-year.
- Protalix BioTherapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $4.47M, a 49.00% increase year-over-year.
- Protalix BioTherapeutics, Inc. research and development expense for fiscal 2025 was $19.57M, a 50.88% increase from fiscal 2024.
- Protalix BioTherapeutics, Inc. research and development expense for fiscal 2024 was $12.97M, a 24.12% decline from fiscal 2023.
- Protalix BioTherapeutics, Inc. research and development expense for fiscal 2023 was $17.09M, a 41.76% decline from fiscal 2022.
- Protalix BioTherapeutics, Inc. research and development expense for fiscal 2022 was $29.35M, a 1.29% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $4.35M 10-Q · filed 2026-08-12 | $9.78M 10-Q · filed 2026-08-12 | $15.41M derived: sum of 3 quarters · filed 2026-08-12 | $19.88M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2026-03-31 | $5.43M 10-Q · filed 2026-05-13 | $11.06M derived: sum of 2 quarters · filed 2026-05-13 | $15.53M derived: sum of 3 quarters · filed 2026-05-13 | $21.52M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-12-31 | $5.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $10.10M derived: sum of 2 quarters · filed 2026-03-18 | $16.09M derived: sum of 3 quarters · filed 2026-08-12 | $19.57M 10-K · filed 2026-03-18 | ||||
| 2025-09-30 | $4.47M 10-Q · filed 2025-11-13 | $10.46M derived: sum of 2 quarters · filed 2026-08-12 | $13.93M 10-Q · filed 2025-11-13 | $18.06M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-06-30 | $5.99M 10-Q · filed 2026-08-12 | $9.47M 10-Q · filed 2026-08-12 | $13.59M derived: sum of 3 quarters · filed 2026-08-12 | $16.59M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-03-31 | $3.48M 10-Q · filed 2026-05-13 | $7.60M derived: sum of 2 quarters · filed 2026-05-13 | $10.60M derived: sum of 3 quarters · filed 2026-05-13 | $13.56M derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2024-12-31 | $4.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $7.12M derived: sum of 2 quarters · filed 2026-03-18 | $10.08M derived: sum of 3 quarters · filed 2026-03-18 | $12.97M 10-K · filed 2026-03-18 | ||||
| 2024-09-30 | $3.00M 10-Q · filed 2025-11-13 | $5.96M derived: sum of 2 quarters · filed 2025-11-13 | $8.85M 10-Q · filed 2025-11-13 | $11.95M derived: sum of 4 quarters · filed 2026-03-18 | ||||
| 2024-06-30 | $2.96M 10-Q · filed 2025-08-14 | $5.85M 10-Q · filed 2025-08-14 | $8.95M derived: sum of 3 quarters · filed 2026-03-18 | $12.62M derived: sum of 4 quarters · filed 2026-03-18 | ||||
| 2024-03-31 | $2.89M 10-Q · filed 2025-05-09 | $5.99M derived: sum of 2 quarters · filed 2026-03-18 | $9.66M derived: sum of 3 quarters · filed 2026-03-18 | $14.13M derived: sum of 4 quarters · filed 2026-03-18 | ||||
| 2023-12-31 | $3.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $6.77M derived: sum of 2 quarters · filed 2026-03-18 | $11.25M derived: sum of 3 quarters · filed 2026-03-18 | $17.09M 10-K · filed 2026-03-18 | ||||
| 2023-09-30 | $3.67M 10-Q · filed 2024-11-14 | $8.14M derived: sum of 2 quarters · filed 2024-11-14 | $13.99M 10-Q · filed 2024-11-14 | $19.61M derived: sum of 4 quarters · filed 2025-03-17 | ||||
| 2023-06-30 | $4.47M 10-Q · filed 2024-08-14 | $10.32M 10-Q · filed 2024-08-14 | $15.94M derived: sum of 3 quarters · filed 2025-03-17 | $23.32M derived: sum of 4 quarters · filed 2025-03-17 | ||||
| 2023-03-31 | $5.85M 10-Q · filed 2024-05-10 | $11.46M derived: sum of 2 quarters · filed 2025-03-17 | $18.85M derived: sum of 3 quarters · filed 2025-03-17 | $26.43M derived: sum of 4 quarters · filed 2025-03-17 | ||||
| 2022-12-31 | $5.62M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $13.00M derived: sum of 2 quarters · filed 2025-03-17 | $20.58M derived: sum of 3 quarters · filed 2025-03-17 | $29.35M 10-K · filed 2025-03-17 | ||||
| 2022-09-30 | $7.39M 10-Q · filed 2023-11-06 | $14.96M derived: sum of 2 quarters · filed 2023-11-06 | $23.73M 10-Q · filed 2023-11-06 | $31.37M derived: sum of 4 quarters · filed 2024-03-14 | ||||
| 2022-06-30 | $7.58M 10-Q · filed 2023-08-07 | $16.35M 10-Q · filed 2023-08-07 | $23.99M derived: sum of 3 quarters · filed 2024-03-14 | $31.27M derived: sum of 4 quarters · filed 2024-03-14 | ||||
| 2022-03-31 | $8.77M 10-Q · filed 2023-05-04 | $16.41M derived: sum of 2 quarters · filed 2024-03-14 | $23.69M derived: sum of 3 quarters · filed 2024-03-14 | $31.38M derived: sum of 4 quarters · filed 2024-03-14 | ||||
| 2021-12-31 | $7.64M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $14.92M derived: sum of 2 quarters · filed 2024-03-14 | $22.61M derived: sum of 3 quarters · filed 2024-03-14 | $29.73M 10-K · filed 2024-03-14 | ||||
| 2021-09-30 | $7.28M 10-Q · filed 2022-11-14 | $14.97M derived: sum of 2 quarters · filed 2022-11-14 | $22.09M 10-Q · filed 2022-11-14 | $33.05M derived: sum of 4 quarters · filed 2023-02-27 | ||||
| 2021-06-30 | $7.69M 10-Q · filed 2022-08-15 | $14.81M 10-Q · filed 2022-08-15 | $25.76M derived: sum of 3 quarters · filed 2023-02-27 | $33.45M derived: sum of 4 quarters · filed 2023-02-27 | ||||
| 2021-03-31 | $7.12M 10-Q · filed 2022-05-16 | $18.07M derived: sum of 2 quarters · filed 2023-02-27 | $25.76M derived: sum of 3 quarters · filed 2023-02-27 | $34.95M derived: sum of 4 quarters · filed 2023-02-27 | ||||
| 2020-12-31 | $10.95M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $18.64M derived: sum of 2 quarters · filed 2023-02-27 | $27.83M derived: sum of 3 quarters · filed 2023-02-27 | $38.17M 10-K · filed 2023-02-27 | ||||
| 2020-09-30 | $7.69M 10-Q · filed 2021-11-15 | $16.87M derived: sum of 2 quarters · filed 2021-11-15 | $27.21M 10-Q · filed 2021-11-15 | $36.81M derived: sum of 4 quarters · filed 2022-03-31 | ||||
| 2020-06-30 | $9.19M 10-Q · filed 2021-08-16 | $19.53M 10-Q · filed 2021-08-16 | $29.12M derived: sum of 3 quarters · filed 2022-03-31 | $39.12M derived: sum of 4 quarters · filed 2022-03-31 | ||||
| 2020-03-31 | $10.34M 10-Q · filed 2021-05-14 | $19.93M derived: sum of 2 quarters · filed 2022-03-31 | $29.93M derived: sum of 3 quarters · filed 2022-03-31 | $43.26M derived: sum of 4 quarters · filed 2022-03-31 | ||||
| 2019-12-31 | $9.60M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $19.59M derived: sum of 2 quarters · filed 2022-03-31 | $32.92M derived: sum of 3 quarters · filed 2022-03-31 | $44.62M 10-K · filed 2022-03-31 | $44.69M 10-K · filed 2020-03-12 | |||
| 2019-09-30 | $10.00M 10-Q · filed 2020-10-29 | $23.32M derived: sum of 2 quarters · filed 2020-10-29 | $35.02M 10-Q · filed 2020-10-29 | $44.60M derived: sum of 4 quarters · filed 2021-03-30 | ||||
| 2019-06-30 | $13.32M 10-Q · filed 2020-08-10 | $25.02M 10-Q · filed 2020-08-10 | $25.02M 10-Q · filed 2019-08-08 | $34.60M derived: sum of 3 quarters · filed 2021-03-30 | $44.67M derived: sum of 4 quarters · filed 2021-03-30 | |||
| 2019-03-31 | $11.70M 10-Q · filed 2020-06-01 | $11.70M 10-Q · filed 2019-05-06 | $21.27M derived: sum of 2 quarters · filed 2021-03-30 | $31.34M derived: sum of 3 quarters · filed 2021-03-30 | $38.82M derived: sum of 4 quarters · filed 2021-03-30 | |||
| 2018-12-31 | $9.57M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-30 | $19.65M derived: sum of 2 quarters · filed 2021-03-30 | $27.12M derived: sum of 3 quarters · filed 2021-03-30 | $33.33M 10-K · filed 2021-03-30 | $35.53M 10-K · filed 2019-03-18 | |||
| 2018-09-30 | $10.07M 10-Q · filed 2019-11-07 | $10.80M 10-Q · filed 2018-11-07 | $17.55M derived: sum of 2 quarters · filed 2019-11-07 | $23.75M 10-Q · filed 2019-11-07 | $25.57M 10-Q · filed 2018-11-07 | $34.61M derived: sum of 4 quarters · filed 2020-03-12 | ||
| 2018-06-30 | $7.48M 10-Q · filed 2019-08-08 | $14.76M 10-Q · filed 2019-08-08 | $24.54M derived: sum of 3 quarters · filed 2020-03-12 | $31.66M derived: sum of 4 quarters · filed 2020-03-12 | ||||
| 2018-03-31 | $7.29M 10-Q · filed 2019-05-06 | $17.07M derived: sum of 2 quarters · filed 2020-03-12 | $24.18M derived: sum of 3 quarters · filed 2020-03-12 | $33.49M derived: sum of 4 quarters · filed 2020-03-12 | ||||
| 2017-12-31 | $9.78M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $16.90M derived: sum of 2 quarters · filed 2020-03-12 | $26.20M derived: sum of 3 quarters · filed 2020-03-12 | $32.17M 10-K · filed 2020-03-12 | ||||
| 2017-09-30 | $7.12M 10-Q · filed 2019-03-18 | $16.42M derived: sum of 2 quarters · filed 2019-03-18 | $22.39M 10-Q · filed 2019-03-18 | $29.10M derived: sum of 4 quarters · filed 2019-03-18 | ||||
| 2017-06-30 | $9.30M 10-Q · filed 2019-03-18 | $15.27M 10-Q · filed 2019-03-18 | $21.98M derived: sum of 3 quarters · filed 2019-03-18 | $28.34M derived: sum of 4 quarters · filed 2019-03-18 | ||||
| 2017-03-31 | $5.97M 10-Q · filed 2019-03-18 | $12.68M derived: sum of 2 quarters · filed 2019-03-18 | $19.03M derived: sum of 3 quarters · filed 2019-03-18 | $29.05M derived: sum of 4 quarters · filed 2019-03-18 | ||||
| 2016-12-31 | $6.71M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $13.06M derived: sum of 2 quarters · filed 2019-03-18 | $23.08M derived: sum of 3 quarters · filed 2019-03-18 | $30.41M 10-K · filed 2019-03-18 | ||||
| 2016-09-30 | $6.35M 10-Q · filed 2017-11-08 | $16.37M derived: sum of 2 quarters · filed 2017-11-08 | $23.70M 10-Q · filed 2017-11-08 | $31.40M derived: sum of 4 quarters · filed 2018-03-06 | ||||
| 2016-06-30 | $10.01M 10-Q · filed 2017-08-09 | $17.35M 10-Q · filed 2017-08-09 | $25.05M derived: sum of 3 quarters · filed 2018-03-06 | $30.11M derived: sum of 4 quarters · filed 2018-03-06 | ||||
| 2016-03-31 | $7.33M 10-Q · filed 2017-05-10 | $15.03M derived: sum of 2 quarters · filed 2018-03-06 | $20.10M derived: sum of 3 quarters · filed 2018-03-06 | $26.12M derived: sum of 4 quarters · filed 2018-03-06 | ||||
| 2015-12-31 | $7.70M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-06 | $12.77M derived: sum of 2 quarters · filed 2018-03-06 | $18.79M derived: sum of 3 quarters · filed 2018-03-06 | $24.89M 10-K · filed 2018-03-06 | ||||
| 2015-09-30 | $5.07M 10-Q · filed 2016-11-09 | $5.26M 10-Q · filed 2015-11-09 | $11.09M derived: sum of 2 quarters · filed 2016-11-09 | $17.19M 10-Q · filed 2016-11-09 | $18.49M 10-Q · filed 2015-11-09 | $21.26M derived: sum of 4 quarters · filed 2017-03-16 | ||
| 2015-06-30 | $6.02M 10-Q · filed 2016-08-08 | $6.47M 10-Q · filed 2015-08-10 | $12.12M 10-Q · filed 2016-08-08 | $13.23M 10-Q · filed 2015-08-10 | $16.20M derived: sum of 3 quarters · filed 2017-03-16 | $24.25M derived: sum of 4 quarters · filed 2017-03-16 | ||
| 2015-03-31 | $6.10M 10-Q · filed 2016-05-09 | $6.76M 10-Q · filed 2015-05-07 | $10.17M derived: sum of 2 quarters · filed 2017-03-16 | $18.22M derived: sum of 3 quarters · filed 2017-03-16 | $25.30M derived: sum of 4 quarters · filed 2017-03-16 | |||
| 2014-12-31 | $4.07M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $12.12M derived: sum of 2 quarters · filed 2017-03-16 | $19.20M derived: sum of 3 quarters · filed 2017-03-16 | $27.35M 10-K · filed 2017-03-16 | $29.76M 10-K · filed 2015-03-12 | |||
| 2014-09-30 | $8.05M 10-Q · filed 2015-11-09 | $15.13M derived: sum of 2 quarters · filed 2015-11-09 | $23.28M 10-Q · filed 2015-11-09 | $29.04M derived: sum of 4 quarters · filed 2016-03-08 | ||||
| 2014-06-30 | $7.08M 10-Q · filed 2015-08-10 | $15.23M 10-Q · filed 2015-08-10 | $20.99M derived: sum of 3 quarters · filed 2016-03-08 | $28.71M derived: sum of 4 quarters · filed 2016-03-08 | ||||
| 2014-03-31 | $8.15M 10-Q · filed 2015-05-07 | $13.91M derived: sum of 2 quarters · filed 2016-03-08 | $21.63M derived: sum of 3 quarters · filed 2016-03-08 | $29.62M derived: sum of 4 quarters · filed 2016-03-08 | ||||
| 2013-12-31 | $5.76M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-08 | $13.48M derived: sum of 2 quarters · filed 2016-03-08 | $21.47M derived: sum of 3 quarters · filed 2016-03-08 | $29.23M 10-K · filed 2016-03-08 | $33.31M 10-K · filed 2014-03-13 | |||
| 2013-09-30 | $7.72M 10-Q · filed 2014-11-10 | $15.71M derived: sum of 2 quarters · filed 2014-11-10 | $23.47M 10-Q · filed 2014-11-10 | $32.41M derived: sum of 4 quarters · filed 2015-03-12 | ||||
| 2013-06-30 | $7.99M 10-Q · filed 2014-08-07 | $15.74M 10-Q · filed 2014-08-07 | $24.69M derived: sum of 3 quarters · filed 2015-03-12 | $33.02M derived: sum of 4 quarters · filed 2015-03-12 | ||||
| 2013-03-31 | $7.75M 10-Q · filed 2014-05-08 | $16.70M derived: sum of 2 quarters · filed 2015-03-12 | $25.03M derived: sum of 3 quarters · filed 2015-03-12 | $35.57M derived: sum of 4 quarters · filed 2015-03-12 | ||||
| 2012-12-31 | $8.95M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | $17.27M derived: sum of 2 quarters · filed 2015-03-12 | $27.82M derived: sum of 3 quarters · filed 2015-03-12 | $36.66M 10-K · filed 2015-03-12 | ||||
| 2012-09-30 | $8.33M 10-Q · filed 2013-11-07 | $18.87M derived: sum of 2 quarters · filed 2013-11-07 | $27.72M 10-Q · filed 2013-11-07 | $36.86M derived: sum of 4 quarters · filed 2014-03-13 | ||||
| 2012-06-30 | $10.54M 10-Q · filed 2013-08-08 | $19.39M 10-Q · filed 2013-08-08 | $28.54M derived: sum of 3 quarters · filed 2014-03-13 | $37.88M derived: sum of 4 quarters · filed 2014-03-13 | ||||
| 2012-03-31 | $8.85M 10-Q · filed 2013-05-09 | $17.99M derived: sum of 2 quarters · filed 2014-03-13 | $27.33M derived: sum of 3 quarters · filed 2014-03-13 | $36.10M derived: sum of 4 quarters · filed 2014-03-13 | ||||
| 2011-12-31 | $9.15M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-13 | $18.49M derived: sum of 2 quarters · filed 2014-03-13 | $27.25M derived: sum of 3 quarters · filed 2014-03-13 | $37.82M 10-K · filed 2014-03-13 | ||||
| 2011-09-30 | $9.34M 10-Q · filed 2012-11-07 | $18.11M derived: sum of 2 quarters · filed 2012-11-07 | $28.67M 10-Q · filed 2012-11-07 | $40.72M derived: sum of 4 quarters · filed 2013-02-28 | ||||
| 2011-06-30 | $8.77M 10-Q · filed 2012-08-03 | $19.33M 10-Q · filed 2012-08-03 | $31.38M derived: sum of 3 quarters · filed 2013-02-28 | $37.70M derived: sum of 4 quarters · filed 2013-02-28 | ||||
| 2011-03-31 | $10.56M 10-Q · filed 2012-05-09 | $22.61M derived: sum of 2 quarters · filed 2013-02-28 | $28.93M derived: sum of 3 quarters · filed 2013-02-28 | $39.28M derived: sum of 4 quarters · filed 2013-02-28 | ||||
| 2010-12-31 | $12.04M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-28 | $18.37M derived: sum of 2 quarters · filed 2013-02-28 | $28.71M derived: sum of 3 quarters · filed 2013-02-28 | $37.69M 10-K · filed 2013-02-28 | ||||
| 2010-09-30 | $6.32M 10-Q · filed 2011-11-07 | $16.67M derived: sum of 2 quarters · filed 2011-11-07 | $25.65M 10-Q · filed 2011-11-07 | |||||
| 2010-06-30 | $10.35M 10-Q · filed 2011-08-08 | $19.32M 10-Q · filed 2011-08-08 | ||||||
| 2009-12-31 | $27.39M 10-K · filed 2012-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |